HTR2A and metabolic dysfunction-associated steatohepatitis: We found that physiological or chemical inhibition of Tph1 (LP533401) protected against and/or ameliorated the progression of HFSD-induced NASH via activation of the HTR2A/PPARγ2 pathway.